medicina57巻9号

2020年08月発行

特集 患者満足度の高い便秘診療 便秘を治療する 【薬物治療】

末梢型オピオイド受容体拮抗薬の使い方—ナルデメジンの緩和医療における位置づけ

著者： 結束貴臣¹² 吉原努¹² 岩城慶大²

所属機関： ¹横浜市立大学附属病院緩和医療科 ²横浜市立大学医学部医学科肝胆膵消化器病学教室

ページ範囲：P.1491 - P.1496

Point
◎緩和期の便秘では，オピオイド誘発性とそれ以外の原因に注意する．
◎末梢型オピオイド受容体拮抗薬（ナルデメジン）は，オピオイド誘発性便秘の治療に有用である．
◎ナルデメジンは非がん患者，高齢者，中等度腎機能障害患者に対しても有用である．
◎弱オピオイド（トラマール^®，ワントラム^®，トラムセット^®）でもオピオイド誘発性便秘は起こる．

参考文献

1）Larkin PJ, et al：The management of constipation in palliative care；Clinical practice recommendation. Palliative Med 22：796-807, 2008

2）Bruera E, et al：Constipation and diarrhea. Bruera E, et al（eds）：Textbook of Palliative Medicine, pp554-568, CRC press, Boca Raton, 2006

3）Sykes NP：Constipation and diarrhea. Hanks G, et al（eds）：Oxford Textbook of Palliative Medicine（4th ed）, pp833-850, Oxford University Press, Oxford, 2009

4）Bell TJ, et al：The prevalence, severity, and impact of opioid-induced bowel dysfunction；Results of a US and European patient survey（PROBE 1）. Pain Med 10：35-42, 2009

5）Lacy BE, et al：Bowel disorders. Gastroenterology 150：1393-1407, 2016

6）Ishihara M et al：A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 28：373-381, 2012

7）De Luca A, et al：Insights into opioid action in the intestinal tract. Pharmacol Ther 69：103-115, 1996

8）Müller-Lissner S, et al：Opioid-induced constipation and bowel dysfunction；A clinical guideline. Pain Med 18：1837-1863, 2017

9）Ling GS, et al：Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci 45：1627-1636, 1989

10）日本緩和医療学会（編）：専門家をめざす人のための緩和医療学（改訂第2版），南江堂，2019

11）Ohkubo H, et al：Relationship between stool form and quality of life in patients with chronic constipation；An internet questionnaire survey. Digestion 1-8, 2019

12）日本緩和医療学会 緩和医療ガイドライン作成委員会（編）：がん疼痛の薬物療法に関するガイドライン（2014年版），金原出版，2014

13）Katakami N, et al：Randomized phase Ⅲ and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol 35：3859-3866, 2017

14）Katakami N, et al：Randomized phase Ⅲ and extension studies；Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol 29：1461-1467, 2018

15）Wild J, et al：Safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy；A subgroup analysis of patients ≥65 years of age. Drugs Aging 37：271-279, 2020

16）Webster LR, et al：A renal impairment subgroup analysis of the safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy. J Pain Res 13：605-612, 2020

17）Ozaki A, et al：Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation；A proof of concept, single institutional, two arm, open-label, phase Ⅱ, randomized controlled trial；The MAGNET study. Trials 21：453, 2020

18）Baron R, et al：Tapentadol prolonged release for chronic pain；A review of clinical trials and 5 years of routine clinical practice data. Pain Pract 17：678-700, 2017

19）Mystakidou K, et al：Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer 107：486-492, 2003